Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Next Gen antibodies seeking to mimic Pelareorep + ICI action

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 04, 2022 9:41pm

174 Views

Post# 35005716

RE:RE:RE:RE:Next Gen antibodies seeking to mimic Pelareorep + ICI action

Capitalista wrote:
Lesalpes29 wrote:

If we see a buyout at this price, I will ski in Les Alpes next winter! Of course I will be retired too!

Lesalpes29, I may see you there!. I'm going regardless of ONC's fortunes, as YOLO. Mribel is my chosen venue.

Meribel, nice for you. Been in Chamonix once. Not able to get back there. It was 20 years ago, time goes fast.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"